We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Paradigm Genetics -- PDGM
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
101 8 0 PDGM
Emcee:  tuck Type:  Unmoderated
PDGM is another biotech in lock-up expiration hell. Shares unlocked in January '01, and the 144s have been pouring out. It seems to be mostly VC at this point.

This link should work indefinitely for keeping track of the insider transactions:

From their website:

>>Paradigm Genetics is industrializing the process of gene function determination for four major sectors of the global economy: human health, nutrition, crop production, and industrial products.<<

It is my understanding that charecterization of gene function is a major bottleneck in drug discovery. Their Gene Function Factory technology is manifest in workstations, so PDGM could arguably be a tool company.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
101CLDA is now at $25 and this looks like an all time high--up 90% in the past yearMike McFarland-2/5/2006
100Scrappy company, CLDA! Market Cap 149M, Enterprise Value 141M. GLGC: Market CapMike McFarland-1/26/2006
99Clinical Data Initiates Pivotal Phase III Trial for Novel Antidepressant Thursdanigel bates-1/26/2006
98Clinical Data and IO Informatics <i>The $11.7-million grantMike McFarland-1/24/2006
97CLDA "reorganizing into two operating divisions to be known as Clinical DatMike McFarland-1/21/2006
96Clinical Data, Inc. Announces Collaborative Research Agreement with University onigel bates-1/12/2006
95CLDA shares are up to $20 from around $17.5 in the last several hours of tradinMike McFarland-1/4/2006
94Final numbers Clinical Data will issue 0.01552 of its own shares for each outstMike McFarland-12/20/2005
93Icoria shareholders will get 0.0139 share of Clinical Data common stock for eachMike McFarland-9/20/2005
92Something like 350k shares yesterday, I know that is only $60k, but caught my eyMike McFarland-8/25/2005
91Icor.ob earnings: From the PR As of June 30, 2005, Icoria reported unrestricteMike McFarland-8/16/2005
90>>RESEARCH TRIANGLE PARK, N.C., June 28 /PRNewswire-FirstCall/ -- Paradigmtuck-6/28/2004
89>>RESEARCH TRIANGLE PARK, N.C., June 23 /PRNewswire-FirstCall/ -- Paradigmtuck-6/23/2004
88>>RESEARCH TRIANGLE PARK, N.C., June 21 /PRNewswire-FirstCall/ -- Paradigmtuck-6/21/2004
87>>RESEARCH TRIANGLE PARK, N.C., May 6 /PRNewswire-FirstCall/ -- Paradigm Gtuck-5/6/2004
86Paradigm Receives Second U.S. Patent for Fungicide Target Pathway RESEARCH TRIAnigel bates-4/22/2004
85>>RESEARCH TRIANGLE PARK, N.C., March 22 /PRNewswire-FirstCall/ -- Paradigtuck-3/22/2004
84Thanks for the link.nigel bates-2/10/2004
83PDGM's Alan J Higgins discusses systems biology, biomarkers, and metabolomictuck-2/10/2004
82>>RESEARCH TRIANGLE PARK and PITTSBURGH, Jan. 29 /PRNewswire-FirstCall/ --tuck-1/29/2004
81Rather strange PR. Financial terms mentioned only vaguely only in the headline tuck-12/19/2003
80Paradigm Genetics Signs Fungicide Evaluation Agreement With Bayer CropScience Thnigel bates-11/20/2003
79Paradigm Genetics Signs Two-Year Extension With Bayer CropScience Monday Novembenigel bates-11/17/2003
78Paradigm Genetics Receives U.S. Patent for Fungicide Target; Target Part of Fungnigel bates-10/23/2003
77Paradigm Genetics and University of North Carolina Enter Collaboration To Identinigel bates-9/30/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):